mTORC1-Dependent Protein and Parkinson's Disease: A Mendelian Randomization Study

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• The mTOR pathway regulates neuronal growth and survival, presenting a potential therapeutic target for Parkinson's disease (PD).
• The specific roles of mTORC1 downstream proteins (RPS6K, EIF4EBP, EIF-4E, EIF-4G, EIF4A) in PD pathogenesis are not well understood.

Purpose of the Study:

• To investigate the potential causal relationships between mTORC1 downstream proteins and Parkinson's disease risk.
• To evaluate the therapeutic potential of targeting these proteins for PD treatment.

Main Methods:

• A Mendelian randomization (MR) study was conducted to assess causality.
• Multiple MR methods (IVW, Weighted Median, MR-Egger, MR-PRESSO, MR-RAPS) and sensitivity analyses were employed.

Main Results:

• Elevated EIF4EBP levels showed a significant inverse association with PD risk (OR=0.79, p=0.003).
• Increased EIF4G plasma levels suggested a protective effect against PD (OR=0.85, p=0.014).
• No significant causal links were found for RPS6K, EIF-4E, or EIF4A with PD risk; sensitivity analyses confirmed robustness.

Conclusions:

• Serum EIF4EBP levels play a protective role in Parkinson's disease.
• Pharmacological activation of EIF4EBP activity represents a promising therapeutic avenue for PD.